<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2709-7927</journal-id>
<journal-title><![CDATA[Acta Médica del Centro]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd centro]]></abbrev-journal-title>
<issn>2709-7927</issn>
<publisher>
<publisher-name><![CDATA[Hospital Provincial Clínico Quirúrgico Universitario Arnaldo Milián Castro]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2709-79272021000400488</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Terapia con biomodulina T en pacientes vulnerables a COVID-19]]></article-title>
<article-title xml:lang="en"><![CDATA[Therapy with biomodulin T in vulnerable patients to COVID-19]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Madrigal Mora]]></surname>
<given-names><![CDATA[Liovesky]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Yanes Milián]]></surname>
<given-names><![CDATA[Belkis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Figueiras]]></surname>
<given-names><![CDATA[Miladys Eladia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Provincial Clínico Quirúrgico Universitario &#8220;Arnaldo Milián Castro&#8221;  ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de Villa Clara  ]]></institution>
<addr-line><![CDATA[Santa Clara Villa Clara]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Policlínico &#8220;Mario Muñoz Monroy&#8221;  ]]></institution>
<addr-line><![CDATA[Yaguajay Sancti Spíritus]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>15</volume>
<numero>4</numero>
<fpage>488</fpage>
<lpage>496</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2709-79272021000400488&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2709-79272021000400488&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2709-79272021000400488&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  la biomodulina T tiene acción cito-restauradora e inmunomoduladora al estimular la mitosis linfoblastoide, así normaliza la diferenciación de linfocitos T; en modelos de inflamación aguda, edema e inflamación crónica demostró un efecto antiinflamatorio al modular la respuesta inflamatoria inducida.  Objetivo:  evaluar la respuesta terapeútica de la biomodulina T en pacientes suceptibles al SARS-CoV-2.  Métodos:  se realizó un estudio descriptivo, longitudinal prospectivo, en la Consulta de Inmunología del Hospital &#8220;Arnaldo Milián Castro&#8221;, de la Provincia de Villa Clara, en el período de marzo de 2020 a septiembre de 2020. Se estudiaron un total de 52 pacientes que presentaron antecedentes patológicos personales que los hacían susceptibles a padecer de infección por el virus SARS CoV-2.  Resultados:  se aplicaron métodos de la estadística descriptiva como tablas de frecuencia para las variables edad, sexo, antecedentes patológicos personales y respuesta al tratamiento con biomodulina T. El grupo de edad con mayor comorbilidades fue el de 40 a 59 años, predominó el sexo masculino y la mayoría de los pacientes tenían antecedentes de enfermedad pulmonar obstructiva crónica, diabetes mellitus e hipertensión arterial. El mayor número de pacientes tenían diagnóstico de enfermedades autoinmunes.  Conclusiones:  la respuesta terapeútica fue satisfactoria para todos los grupos de edades.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  the biomodulin T has cyto-restorative and immunomodulatory action by stimulating lymphoblastoid mitosis, in that way the differentiation of T-lymphocytes is normalized; in models of acute inflammation, edema and chronic inflammation showed an anti-inflammatory effect by modulating the induced inflammatory response.  Objective:  to evaluate the therapeutic response of biomodulin T in susceptible patients to SARS-CoV-2.  Methods:  a descriptive, prospective longitudinal study was carried out at the Immunology Clinic from &#8220;Arnaldo Milián Castro&#8221; Hospital, in Villa Clara Province, from March 2020 to September 2020. A total of 52 patients who presented personal pathological antecedents that made them susceptible to suffer from SARS CoV-2 virus infection were studied.  Results:  descriptive statistical methods such as frequency tables for the variables age, sex, personal pathological history and response to treatment with biomodulin T were applied. The age group with the most comorbidities was 40 to 59 years, male sex predominated and most patients had a history of chronic obstructive pulmonary disease, diabetes mellitus and arterial hypertension. The largest number of patients had a diagnosis of autoimmune diseases.  Conclusions:  the therapeutic response was satisfactory for all age groups.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Biomodulina T]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[antecedentes patológicos personales]]></kwd>
<kwd lng="en"><![CDATA[Biomodulin T]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[personal pathological history]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Madrigal Mora]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ferriol González]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Meneses Foyo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Rendimiento académico y factores estresantes en residentes de especialidades quirúrgicas en su examen estatal con enfrentamiento a la COVID-19]]></source>
<year>2021</year>
<conf-name><![CDATA[ IJornada Científica de Farmacología y Salud. Fármaco Salud Artemisa 2021]]></conf-name>
<conf-loc> </conf-loc>
<publisher-loc><![CDATA[Artemisa ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Artemisa]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gou]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Pu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of comorbidities in the Novel Wuhan Coronavirus (COVID-19) infection: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Inter Infect Dis]]></source>
<year>2020</year>
<volume>94</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>91-5</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos</collab>
<source><![CDATA[Biomodulina T]]></source>
<year>2015</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Cecmed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samada Suárez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Perera]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Predomina la mortalidad por la COVID-19 en el sexo masculino?]]></article-title>
<source><![CDATA[Boletín científico del CIMEQ]]></source>
<year>2020</year>
<volume>1</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>6-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>Centro de Estudios Demográficos</collab>
<article-title xml:lang=""><![CDATA[Edición Especial COVID-19]]></article-title>
<source><![CDATA[Boletín INFOPOB]]></source>
<year>2020</year>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>Agencia Cubana de Noticias</collab>
<source><![CDATA[COVID-19: En Cuba, como en el mundo, la edad de contagio se ha "corrido"]]></source>
<year>2020</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ACN]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mizumoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kagaya]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zarebski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chowell]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020]]></article-title>
<source><![CDATA[Euro Surveill]]></source>
<year>2020</year>
<volume>25</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almaguer Mederos]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Cuello Almarales]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Almaguer Gotay]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rol de los genes ACE2 y TMPRSS2 en la susceptibilidad o gravedad de la COVID-19]]></article-title>
<source><![CDATA[AACC]]></source>
<year>2020</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Qu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>395</volume>
<numero>10223</numero>
<issue>10223</issue>
<page-range>507-13</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paules]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Marston]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Fauci]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronavirus Infections-More Than Just the Common Cold]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>323</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>707-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peláez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomodulina T, otro eficaz fármaco cubano contra la COVID-19]]></article-title>
<source><![CDATA[Granma]]></source>
<year>11/0</year>
<month>5/</month>
<day>20</day>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Protocolo de Actuación Nacional para la COVID-19 (Versión 1.3 Abril)]]></source>
<year>2020</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[MINSAP]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
